RALEIGH, N.C., March 14, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it will participate in the Canaccord Genuity Musculoskeletal conference in March.
Ken Reali, President and Chief Executive Officer, and Joe Slattery, Executive Vice President and Chief Financial Officer, are scheduled to present at the Canaccord Genuity Musculoskeletal Conference in Chicago, IL on Tuesday, March 19, 2013 at 11:20 am CT.
Institutional investors that wish to request a meeting with TranS1 should contact Canaccord Genuity.About TranS1 Inc. TranS1 is a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lumbar region. TranS1 currently markets the AxiaLIF® family of products for single and two level lumbar fusion, the VEO TM direct lateral access and interbody fusion system and the Vectre TM posterior fixation system for lumbar fixation supplemental to AxiaLIF fusion. TranS1 was founded in May 2000 and is headquartered in Raleigh, North Carolina. For more information, visit www.trans1.com.
CONTACT: Investors: TranS1 Inc. Joseph P. Slattery, 910-332-1700 Executive Vice-President and Chief Financial Officer Westwicke Partners Mark Klausner, 443-213-0501 firstname.lastname@example.org